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Abstract 
Long-term survival in orthotopic liver transplant (OLT) recipients remains impaired due to 
many contributing factors, among which a low pre-transplant muscle mass (or sarcopenia). 
However, influence of post-transplant muscle mass on survival is currently unknown. We 
hypothesized that post-transplant urinary creatinine excretion rate (CER), an established non-
invasive marker of total body muscle mass, is associated with long-term survival after OLT. 
In a single-center cohort study of 382 adult OLT recipients, mean±standard deviation CER at 
1 year post-transplantation was 13.3±3.7 mmol/24h in men and 9.4±2.6 mmol/24h in women. 
During median follow-up for 9.8y (interquartile range 6.4-15.0y), 104 (27.2%) OLT 
recipients deceased and 44 (11.5%) developed graft failure. In Cox regression analyses, as 
continuous variable, low CER was associated with increased risk for mortality (HR=0.43, 
95%CI: 0.26-0.71, P=0.001) and graft failure (HR=0.42, 95%CI: 0.20-0.90, P=0.03), 
independent of age, sex, and body surface area. Similarly, OLT recipients in the lowest tertile 
had an increased risk for mortality (HR=2.69; 95%CI: 1.47-4.91, P=0.001) and graft failure 
(HR=2.77, 95%CI: 1.04-7.39, P=0.04), compared to OLT recipients in the highest tertile. We 
conclude that 1-year post-transplant low total body muscle mass is associated with long-term 
risk of mortality and graft failure in OLT recipients.  
 
1.Introduction 
Liver transplantation is the treatment of choice for patients with end-stage liver disease.1 
Over the past decades, overall 1- and 5-year survival rates after orthotopic liver 
transplantation (OLT) have steadily increased towards approximately 90% and 70%, 
respectively.2,3 Unfortunately, long-term patient survival rates after OLT lag behind, with an 
overall 20-year survival rate of approximately 50%.4 A recent study showed that at 10 years 
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population.5 Furthermore, worldwide 5-22% of the OLT recipients require 
retransplantation,6,7 which is the only treatment option for patients with graft failure. 
Retransplantation is associated with worse outcome when compared to primary OLT.8–10 
Moreover, a liver assigned for retransplantation cannot be used for primary OLT, resulting in 
increased organ shortage.11 During the past decades no large improvement in long-term 
patient and graft survival in OLT recipients has been achieved, therefore, greater attention 
should be paid to long-term follow-up after OLT.3  
There are multiple factors that determine long-term outcome after OLT, including 
recipient age,12 donor age,13,14 primary diagnosis,15 and disease recurrence.16 The use of 
immunosuppressive medication, and comorbidities including obesity, metabolic syndrome, 
and subsequent malignancies may also contribute to a decreased survival of OLT recipients.17 
However, the influence of many other factors on long-term survival outcomes after OLT are 
still unknown.  
One of these factors could be muscle mass, an important source of amino acids and a 
key player in protein metabolism, which, in turn, is of key importance in the stress 
response.18 Previous studies have shown that low muscle mass is an independent predictor of 
survival in several chronic diseases, including heart failure and cancer.19,20 Moreover, it is 
well established that muscle mass is an indicator of nutritional status in patients who suffer 
from protein-energy malnutrition.21 It has also been demonstrated that protein-energy 
malnutrition is associated with a higher risk of mortality in patients awaiting OLT.22 Pre-
transplant muscle mass, as measured by computed tomography (CT), predicts intensive care 
unit (ICU) state, total length of stay, and days of intubation after OLT.23 However, the role of 
post-transplant low muscle mass has not yet been studied on long-term patient and graft 
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Creatinine is a breakdown product of creatine phosphate in muscle, which is usually 
produced at a constant rate depending on the amount of muscle mass.24 Urinary creatinine 
excretion rate (CER) is therefore an established marker of total body muscle mass in diverse 
populations, among which patients with wasting condition.25–28 Low muscle mass, or 
sarcopenia, is an important comorbid condition in OLT recipients, however, studies 
investigating urinary CER have not yet been performed. We hypothesized that low urinary 
CER was associated with poor long-term survival after OLT. Therefore, the aim of this study 
was to determine whether CER is a prognostic marker of mortality and graft failure in stable 
OLT recipients.  
 
2.Materials and methods 
2.1 Study design and population 
A single center retrospective analysis was performed in all patients aged ≥18 years who 
underwent OLT at the University Medical Center Groningen, the Netherlands, between 
January 1993 and December 2010. All patients received care according to a standardized 
protocol. Baseline was set at one year post-transplantation, since recipients are then 
considered to be stable, and are less likely to develop rejection or infections. OLT recipients 
with missing baseline data on CER, those with a (graft) survival time less than one year, or 
those lost to follow-up were excluded.  
According to the Dutch law, general consent for transplantation and organ donation 
includes consent for research projects. The study protocol was approved by the institutional 
research board (METc 2014/77), and adhered to the Declaration of Helsinki, as well as to the 
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2.2 Data collection and measurements 
Data were retrieved from electronic patient records. Weight, height, etiology, blood pressure, 
medication, and smoking status were derived from patients records. Body Mass Index (BMI) 
was defined as weight divided by height squared (kg/m2). Body Surface Area (BSA) was 
assessed using the DuBois formula.29 A positive cardiovascular history was defined as a 
previous myocardial infarction, cerebrovascular accident, and/or peripheral arterial disease. 
Donor characteristics were collected using the Eurotransplant database.  
 To obtain adequate 24-hour urine samples all patients were required to adhere to a 
standardized protocol. All patients were instructed to start by discarding the urine void at the 
start of collection and to subsequently collect all urine for the next 24-hours, including a void 
at precisely 24-hours after the collection start. To minimize collection and measurement 
errors, a median of all laboratory and 24-hour urinary measurements between 9 and 15 
months post-transplantation was calculated (Supplementary figure S1). The median of these 
measurements was used for analyses. CER, urinary urea excretion, and proteinuria were 
assessed from 24-hour urine collection. Proteinuria was defined as urinary protein excretion 
of >0.5g/day. Data on glucose, total cholesterol, triglycerides, C-reactive protein, hemoglobin 
levels, aspartate transaminase (AST), alanine transaminase (ALT), gamma-
glutamyltransferase (γ-GT), alkaline phosphatase (ALP), direct and total bilirubin, serum 
albumin, and serum creatinine were extracted from the hospital laboratory system. The 
estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation.30 To assess a potential time effect, 
transplantation dates were divided into three consecutive eras based on changes in 
immunosuppressive regimens. The first era was set form 1993 until 1998, the second era was 
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2.3 Immunosuppressive regimens and rejection 
Immunosuppressive therapy was given according to a standardized protocol. Generally, from 
1993 therapy consisted of a combination of prednisolone (10 mg/day), azathioprine (125 
mg/day), and ciclosporin A, resulting in whole-blood levels of ~100µg/L in the first year 
post-transplantation. From 1998 onwards, immunosuppressive therapy consisted of a 
combination of prednisolone and tacrolimus (whole blood levels in the first year between 5-
7µg/L) or a combination of prednisolone, cyclosporin A, and azathioprine. From April 2010, 
the combination of prednisolone, mycophenolate mofetil, and tacrolimus is used by default. 
Variations in the standard regimens were present and were related to side-effects or treatment 
of allograft rejection.31,32 
Acute rejection was diagnosed either clinically or confirmed with a biopsy. If acute 
rejection was present, initial therapy was to optimize levels of tacrolimus. If acute rejection 
persisted, therapy consisted of 1000mg methylprednisolone for three consecutive days.  
Cumulative dose of prednisolone was calculated by multiplying the prednisolone dose 
at baseline by the time since transplantation and adding the dose of prednisolone or 
methylprednisolone required for treatment of acute rejection. A conversion factor of 1.25 was 
used to convert methylprednisolone dose to prednisolone dose. 
 
2.4 Outcome measures 
 The primary outcome of this study was all-cause mortality. The secondary outcomes 
of this study were death-censored graft failure and cause-specific mortality, divided into four 
categories: cardiovascular, infectious, malignancy, and miscellaneous. Death-censored graft 
failure was defined as the requirement for retransplantation. Data on cause-specific mortality 
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general practitioners. Follow-up was recorded up to 15 years after baseline, or until 31st of 
December 2016.  
 
2.5 Statistical analysis  
Normally distributed variables are presented as mean±standard deviation (SD) and skewed 
distributed variables are presented as median (interquartile range [IQR]). Categorical 
variables are presented as a number (percentage). To test for differences across tertiles, one-
way ANOVA tests were used for normally distributed variables, Kruskal-Wallis tests when 
variables were skewed, and Chi-square tests for categorical variables. Since the magnitude of 
muscle mass differs largely between men and woman, stratification was used to minimize a potential 
effect of gender in baseline analyses. All reported p-values are two-tailed and p-values of ≤0.05 
were considered to be statistically significant. For interaction terms a p-value of <0.05 was 
considered to be statistically significant. Patients were censored at date of death or lost to 
follow-up. Coefficients of variation (SD/mean x 100%) were calculated from the CER data 
obtained between 9 and 15 months after OLT.  
Initial survival analysis was performed according to Kaplan-Meier with log-rank 
testing. Furthermore, the proportional hazards assumption was checked using Schoenfeld 
residuals of CER and met the criteria. We continued with Cox-proportional hazards 
regression analyses to study whether CER was associated with all-cause mortality. We first 
performed crude analysis (model 1). Subsequently, we proceeded with multivariable 
analyses. Model 2 was adjusted for age, sex, and BSA. Model 3 was cumulatively adjusted 
for eGFR, proteinuria, primary liver disease, and transplantation era. We additionally 
adjusted for cardiometabolic risk factors, including cardiovascular disease history, smoking, 
systolic blood pressure, and glucose in model 4, use of calcineurin inhibitors and cumulative 
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serum albumin and total cholesterol in model 7. For the association with death-censored graft 
failure, we did not adjust for model 6 and 7, since these parameters are not considered 
potential confounders. In continuous Cox proportional hazards regression models, CER was 
log-base 2 transformed to allow for expression of the HRs per doubling of CER. In addition, 
CER was used as categorical variable for analyses by tertiles. Data were presented as hazard 
ratios (HR) and 95% confidence intervals (CI). Furthermore, we evaluated potential effect 
modification by age, sex, BSA, renal function, urinary protein excretion, smoking, and serum 
albumin. Additionally, we have collected data on CER between 3 and 9 months post-
transplantation to calculate a median urinary CER around 6-months post-transplantation and 
calculated CER change (CER1year – CER6months/ CER6months). To put the magnitude of CER 
into context additional Cox regression analyses, expressing HRs per SD change, were 
performed.  
For visually depiction of the non-linear relationship between CER and mortality, we 
made restricted cubic splines with three knots positioned at the 10th, 50th, and 90th percentile. 
To use the median of the third tertile of CER as reference in the analysis for restricted cubic 
splines, the standard errors of the difference in HR of each individual point compared to the 
reference was computed by bootstrapping by 1000 cycli.  
Statistical analyses were performed using IBM Statistics SPSS version 23.0 (IBM Inc. 
Chicago, IL, USA), GraphPad Prism 5 (La Jolla, CA, USA), STATA 11.0 (STATA Corp.), 
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3.Results 
3.1 Baseline characteristics 
Between 1993-2010 a total of 393 patients ≥18 years underwent OLT. Ten OLT recipients 
with missing baseline data on CER or death within first year were excluded. One recipient 
was lost to follow-up. Subsequently, 382 OLT recipients (58.9% men) were included for 
analyses with a mean age of 48.5±12.5 years. Mean (of median individual) CER at 1-year 
post-transplant was 13.3±3.7 mmol/24h in men and 9.4±2.6 mmol/24h in women (P<0.001). 
The median coefficient of variation of the CER data obtained between 9 and 15 months after 
liver transplantation was 19.5 (12.6-25.8)%. Baseline characteristics according to sex-
stratified tertiles of CER are shown in table 1. OLT recipients in the lowest tertile were 
significantly older, smoked more frequently, and were smaller when compared to OLT 
recipients in the highest tertile. Furthermore, patients in the lowest tertile had a lower body 
weight, lower BMI, lower BSA, higher total cholesterol, lower hemoglobin, and lower 
albumin levels when compared to patients in the highest tertile. Moreover, liver enzymes 
were significantly higher in OLT recipients in the lowest tertile when compared to OLT 
recipients in the highest tertile. Lastly, cumulative dose of prednisolone was lower in patients 
in the lowest tertile compared to patients in the highest tertile, while prednisolone dose at 
baseline and number of OLT recipients using prednisolone at baseline did not differ. There 
were no differences in renal function, transplant characteristics and use of medication other 
than prednisolone. The median CER according to categories of primary liver disease for the 
overall OLT recipient population and according to sex stratified tertiles of CER is shown in 
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3.2 Association of CER with all-cause mortality & graft failure  
During a median follow-up for 9.8 (6.4-15.0) years, 104 (27.2%) OLT recipients 
deceased, and 44 (11.5%) OLT recipients developed death-censored graft failure. Over sex-
stratifed tertiles of CER, 43 (33.9%) OLT recipients died in the 1st tertile, 35 (27.3%) died in 
the 2nd tertile, and 26 (20.5%) died in the 3rd tertile (figure 1a, log-rank test: P=0.009). For 
death-censored graft failure, 17 (13.4%) OLT recipient needed retransplantation in the 1st 
tertile, while 17 (13.3%) and 10 (7.9%) OLT recipients needed retransplantation in 
respectively the 2nd and 3rd tertile (figure 1b, log-rank test: P=0.09).  
We proceeded with Cox-regression analyses and checked for potential interactions of 
CER with age, sex, BSA, renal function, urinary protein excretion, smoking, and serum 
albumin. For both all-cause mortality and death-censored graft failure no significant 
interactions were identified (all P≥0.05), when adjusted for age, sex, and BSA. 
Cox regression analyses for CER as log-transformed continuous variable showed a 
significant association with all-cause mortality (HR=0.43 per doubling of CER; 95%CI: 0.26-
0.71, P=0.001), and death-censored graft failure (HR=0.42 per doubling of CER; 95%CI: 
0.20-0.90, P=0.03), independent of age, sex, and BSA (table 3-4, model 2). These 
associations are graphically depicted in non-linear restricted cubic splines (figure 2). Further 
adjustment for eGFR, proteinuria, primary liver disease, and transplantation era did not 
materially change the association of CER with all-cause mortality (HR=0.47; 95%CI: 0.28-
0.81, P=0.006) and graft failure (HR=0.40; 95%CI: 0.19-0.84, P=0.02) (table 3-4, model 3). 
Adjusting for cardiovascular disease history, smoking, SBP, glucose, calcineurin inhibitors, 
cumulative prednisolone dose, liver enzymes, direct bilirubin, serum albumin, and total 
cholesterol did not materially change the results for all-cause mortality (table 3, models 4-7) 
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 We continued with Cox proportional hazard models to study the associations 
according to tertiles of CER. OLT recipients with low CER levels (1st tertile) appeared to be 
at an approximately 2.5-fold higher risk of all-cause mortality (HR=2.58; 95%CI: 1.35-4.93, 
P=0.004), and 3-fold higher risk of graft failure (HR=3.20; 95%CI: 1.21-8.44, P=0.02), when 
compared to OLT recipients in the 3rd tertile, independent of potential confounders including 
age, sex, BSA, eGFR, proteinuria, primary liver disease, and transplantation era (table 3, 
model 3). Adjusting for other potential confounders did not materially change the results for 
all-cause mortality and graft failure (table 3, models 4-7; table 4, models 4-5). 
To investigate the association of CER with cause-specific mortality, we performed 
additional Cox-regression analyses (Supplemental Table 1). We found a significant 
association of CER with cardiovascular mortality (model 3, HR 0.77; 95%CI 0.66-0.89, p < 
0.001). No statistically significant associations were found for CER with infectious, 
malignant, and miscellaneous mortality. Furthermore, there was a significant association of 
CER around 6-months post-transplantation with all-cause mortality (model 3, HR: 0.54; 
95%CI: 0.33-0.88, p = 0.01), which was independent of age, sex, BSA, eGFR, proteinuria, 
primary liver disease, and transplantation era. We did not find a significant association of 
CER around 6-months after transplantation with graft failure (Supplemental Table 2). 
Additional analyses were performed to assess the association of change in CER with all-
cause mortality and death-censored graft failure (Supplemental Table 3). Change in CER was 
not predictive for all-cause mortality, while CER measured at 1-year post-transplant and 6-
months post-transplant were. However, change in CER was predictive for graft failure, while 
CER at 6-months post-transplant was not. When comparing the magnitude of CER with other 
potential variables of interest additional Cox regression analyses revealed muscle mass to 
have a similar magnitude for the association with mortality as glucose and BMI 
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4.Discussion 
In this study, we demonstrated that a low post-transplant total body muscle mass, as 
measured by urinary CER, was inversely associated with an increased risk of long-term all-
cause mortality and graft failure in OLT recipients. The risk for all-cause mortality was more 
than 2.5-fold higher and the risk for death-censored graft failure was 3-fold higher in the 
lowest tertile when compared to the highest tertile of CER. The current results underline the 
importance of an adequate post-transplant total body muscle mass on long-term survival post-
OLT.  
To the best of our knowledge, we are the first to investigate the association of post-
transplant total body muscle mass, as reflected by urinary CER, with long-term all-cause 
mortality and graft failure in OLT recipients. Urinary CER is an inexpensive, accessible, and 
reliable marker in stable patients and in patients with wasting conditions, without the need for 
invasive procedures or exposure to radiation.24,28  
Muscle mass, as reflected by CER, has been associated with the development of 
cardiovascular disease and all-cause mortality in the general population.25 As mentioned, 
OLT recipients have about 20% reduced survival rates when compared to the general 
population.5 This magnitude of survival rate was similar for OLT recipients in the 3rd tertile 
in our study. However, a decrease of almost 30% in survival rate was observed in OLT 
recipients in the 1st tertile, emphasizing the importance of muscle mass for OLT recipients. 
Results in the general population are consistent with the results from other 
populations, namely that CER has been associated with mortality, independently of age and 
sex in patients with coronary artery disease, type 2 diabetes, and heart failure.27,33,34 In 
addition, CER has been shown to predict all-cause mortality and graft failure in renal 
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To date, focus has predominantly been on pre-transplant muscle mass and its effect on 
adverse outcomes post-transplantation. Yet, we would advocate that attention on muscle 
mass, the anabolic influence of dietary interventions, and physical activity on longer term 
post-transplantation is warranted. Regrettably, CT is usually not part of routine post-
transplantation follow-up. Moreover, it requires exposure to radiation, is expensive, and like 
magnetic resonance imaging (MRI), does not allow for whole body muscle mass 
measurement, which is reflected by CER. In addition, CT and MRI measurements may lead 
to over- or underestimation of muscle mass. CT and MRI lack the capability for specific 
tissue differentiation between edema and fatty infiltration in muscle mass which could lead to 
overestimation. On the other hand, in wasting conditions connective, neural, and vascular 
tissue do not atrophy as much as muscle mass, which in turn could lead to 
underestimation.24,35  
Sarcopenia or loss of skeletal muscle mass is the major component of malnutrition 
and is a frequent complication in chronic liver disease and cirrhosis that adversely affects 
clinical outcomes.36 Since etiology and severity of the underlying liver disease may 
significantly contribute to the severity of loss of skeletal muscle mass,36 it could be 
hypothesized that these patients have different levels of urinary CER post-transplantation. In 
our study, levels of post-transplant CER did not differ across categories of primary liver 
disease, indicating that disease etiology was not associated with skeletal muscle mass status, 
as measured by urinary CER 1-year post-transplantation. 
Liver transplantation is expected to abolish the abnormalities in nutritional status and 
in dietary intake. By restoring liver function, maintenance of protein synthesis and the liver’s 
ability to regulate energy metabolism is recovered, presumably eliminating the metabolic 
alterations involved in the pathophysiology of malnutrition in cirrhotic patients.37 
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OLT recipients prone to muscle wasting.38 Unfortunately, meticulous evaluation of 
mechanisms responsible for loss of muscle mass has not yet been performed. As a result, 
protein-energy malnutrition can still be observed in OLT recipients, greatly increasing 
recipients risks for mortality.22,39 Although the impact of post-transplantation malnutrition on 
graft failure has not yet been studied in OLT recipients and a potential mechanism is 
unknown, protein-energy malnutrition has been associated with graft loss in renal transplant 
recipients.40 In this study, causal pathway analyses revealed muscle mass to be an 
explanatory component. Therefore, we hypothesize that protein-energy malnutrition may also 
increase the risk for graft loss in OLT recipients.  
Although muscle mass is often not regained post-transplantation, a substantial 
increase in body weight can be observed. Most OLT recipients gain an average of 5.1 kg, in 
the first year post-transplantation.41 This gain of mostly fat mass increases in subsequent 
years and is accelerated by poor lifestyle factors, including an approximately doubled fat 
intake compared to pre-transplantation, reduced physical activity, and immunosuppressive 
medication.41–43 As a result, an increased prevalence of obesity and new onset diabetes after 
transplantation, and an increased risk of metabolic syndrome and mortality in OLT recipients 
can be observed.41,44,45  
As mentioned, OLT recipients have reduced levels of physical activity compared with 
age-predicted levels in healthy populations.46,47 Physical activity has a large impact on weight 
management and is known to improve exercise capacity and muscular strength.47 The latter 
has been shown to be inversely associated with hypertension in OLT recipients and mortality 
in cirrhotic patients.48,49 Furthermore, the same entities that could lead to a poor muscle mass 
are suspected to give rise to low physical activity. Hence, muscle mass could be an indirect 
measure of physical activity and therefore explain the results found in this study. 
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recovery from transplantation. However, to the best of our knowledge, studies on nutritional 
and physical-activity-based interventions to regain muscle mass and improve long-term 
outcome are lacking.50 Nevertheless, there are some studies that show the effects of nutrition 
and physical activity on short-term outcomes. A previous retrospective study showed that 
perioperative nutritional therapy improved short-term survival in patients with sarcopenia 
who underwent living donor liver transplantation.51 Furthermore, a randomized clinical trial 
in OLT recipients showed that combined intervention of home-based exercise and dietary 
modification improved exercise capacity (measured by VO2peak) and self-reported general 
health.52 Future studies focusing on interventions to improve muscle mass and long-term 
clinical outcomes post-transplantation are warranted.  
A valuable strength of this study is that CER was measured multiple times over a 6-
month period. Utilizing the median of multiple measurements reduces the influence of 
measurement errors. Another strength of this study is its sizeable population, the long median 
follow-up of 9.8 years, and that the loss to follow-up was comprised by only one patient. 
The current study has some limitations. Previous studies have speculated on the role 
of nutrition in preventing muscle loss in OLT recipients.37,47 Unfortunately, in this study 24h 
urinary urea excretion, as marker for protein intake, was only available in 17.2% of OLT 
recipients, discarding its utility for analyses. Other limitations are the lack of assessments of 
muscle mass before and right after transplantation and that data on non-compliance and 
physical activity was not available. Furthermore, liver biopsies to assess the distribution of 
fibrosis or cirrhosis were not routinely performed. The fact that our study is a single-center 
cohort study, could limit external validity of its findings.  
In conclusion, lower post-transplant urinary CER was inversely associated with an 
increased risk of both all-cause mortality and graft failure in OLT recipients. In addition, we 
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higher risk for graft failure in the lowest tertile when compared to the highest tertile of CER. 
Further research is warranted to investigate possible mechanisms responsible for loss of 
muscle mass after liver transplantation. 
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Figure Legends 
 
Figure 1. Kaplan Meier curves for all-cause mortality (A) and graft failure (B) according to 
sex-stratified tertiles of CER in 382 OLT recipients. 
CER, creatinine excretion rate 
Figure 2. Association of log-transformed (HR per doubling of) CER on all-cause mortality 
and graft failure in 382 OLT recipients. Data were fit by a Cox proportional regression model 
with time-varying covariates based on restricted cubic splines with 3 knots. Adjusted for age, 
sex, and BSA. Reference standard was the median CER of the 3rd tertile (i.e. 3.9 mmol/24h 
log-transformed per doubling of CER equivalent to a CER of 15.1 mmol/24h). The grey area 
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Table 1. Baseline characteristics of the overall OLT recipient population and according to sex stratified tertiles of creatinine excretion rate. 
 Overall OLT recipients 








   Men (n) 221 74 73 74  
       Creatinine excretion (mmol/24h) 13.1 (10.7-15.4) 9.6 (8.6-10.7) 13.1 (12.4-13.8) 16.6 (15.4-18.9) 
   Women (n) 161 51 56 54 
      Creatinine excretion (mmol/24h) 9.2 (7.7-11.1) 6.8 (5.9-7.5) 9.1 (8.5-9.9) 11.8 (11.0-13.2) 
Demographics 
   Age, years 48.5 ± 12.5 49.3 ± 12.1 50.1 ± 12.6 46.2 ± 12.4 0.03 
   Current smoker, n (%) 50 (13.1) 23 (18.4) 22 (17.1) 5 (3.9) 0.005 
Body composition  
   Height, m 1.7 ± 0.1 1.7 ± 0.1 1.7 ± 0.1 1.8 ± 0.1 0.001 
   Weight, kg 77.0 ± 14.7 73.1 ± 14.9 75.9 ± 13.4 81.8 ± 14.5 < 0.001 
   BMI, kg/m2 25.7 ± 4.6 25.3 ± 5.2 25.2 ± 4.0 26.7 ± 4.3 0.02 
   BSA, m2 1.9 ± 0.2 1.8 ± 0.2 1.9 ± 0.2 2.0 ± 0.2 < 0.001 
Medical history      
   Cardiovascular disease history, n (%) 19 (5.0) 9 (7.2) 2 (2.3) 7 (5.5) 0.19 
   Hypertension, n (%) 231 (60.5) 70 (56.0) 84 (65.1) 77 (60.2) 0.39 
Circulation 
   Heart rate, b.p.m. 73.5 ± 10.1 73.4 ± 10.8 72.3 ± 10.3 74.6 ± 9.2 0.35 
   SBP, mmHg 133.1 ± 15.4 134.8 ± 18.4 131.9 ± 14.5 132.7 ± 13.0 0.32 
   DBP, mmHg 81.8 ± 9.2 80.9 ± 10.8 81.4 ± 8.0 82.8 ± 8.7 0.24 
Renal function 
   eGFR, ml/min per 1.73 m2 69.4 ± 21.9 69.6 ± 23.7 67.3 ± 20.4 71.2 ± 21.5 0.36 
   Serum creatinine, umol/L 105.0 ± 40.0 106.2 ± 38.3 105.4 ± 27.3 103.3 ± 26.4 0.74 
   Proteinuria, n (%) 43 (11.3) 18 (14.4) 14 (10.9) 11 (8.6) 0.33 
Laboratory parameters 
   Triglycerides, mmol/L 1.5 (1.1 – 2.2) 1.6 (1.2 – 2.4) 1.5 (1.0 – 2.1) 1.5 (1.2 – 2.1) 0.41 
   Total cholesterol, mmol/L 5.0 ± 1.4 5.2 ± 1.6 5.1 ± 1.4 4.8 ± 1.1 0.03 
   HDL cholesterol, mmol/L 1.3 ± 0.5 1.1 ± 0.4 1.4 ± 0.5 1.4 ± 0.4 0.11 
   Glucose, mmol/L 5.7 (4.7 – 6.6) 5.8 (4.9 – 6.9) 5.6 (4.8 – 6.9) 5.6 (4.6 – 6.4) 0.19 
   HbA1C, %  6.7 (5.5 – 19.1) 6.7 (5.7 – 17.5) 6.6 (5.5 – 17.6) 7.0 (5.6 – 21.8) 0.53 
   Hemoglobin, mmol/L 7.9 ± 1.2 7.6 ± 1.5 8.1 ± 1.0 8.1 ± 0.8 0.001 
   Albumin, g/L 41.7 ± 4.6 40.1 ± 5.5 42.1 ± 4.3 42.7 ± 3.5 < 0.001 
   CRP, mg/L 5.0 (5.0 – 21.3) 8.6 (5.0 – 27.4) 5.0 (5.0 – 20.8) 5.0 (5.0 – 15.0) 0.21 
   AST, U/L 26.7 (21.2 – 39.8) 34.0 (23.1 – 61.8) 26.7 (21.6 – 38.7) 24.2 (20.1 – 32.0) < 0.001 
   ALT, U/L 28.5 (19.0 – 49.9) 38.0 (22.0 – 74.7) 28.0 (18.5 – 47.9) 25.2 (18.8 – 36.4) < 0.001 
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   ALP, U/L 87.4 (65.0 – 127.1) 113.6 (73.1 – 167.4) 86.0 (60.7 – 124.4) 73.4 (59.7 – 103.7) < 0.001 
   Bilirubin total, μmol/L 16.5 (11.5 – 24.0) 16.7 (12.2 – 29.5) 16.0 (11.2 – 23.2) 16.0 (11.5 – 22.5) 0.52 
   Bilirubin direct, μmol/L 5.8 (3.0 – 10.0) 6.5 (3.6 – 12.7) 5.9 (3.0 – 9.9) 5.0 (3.0 – 8.1) 0.08 
Primary liver disease 0.06 
   Acute liver failure, n (%) 24 (6.3) 3 (2.4) 11 (8.5) 10 (7.8)  
   Viral hepatitis, n (%) 55 (14.4) 25 (20.0) 16 (12.4) 14 (10.9) 
   Auto-immune hepatitis, n (%) 29 (7.6) 8 (6.4) 10 (7.8) 11 (8.6) 
   Primary biliary cholangitis, n (%) 33 (8.6) 12 (9.6) 8 (6.2) 13 (10.2) 
   Primary sclerosing cholangitis, n (%) 75 (19.6) 16 (12.8) 23 (17.8) 36 (28.1) 
   Cryptogenic cirrhosis + NASH, n (%) 46 (12.0) 19 (15.2) 17 (13.2) 10 (7.8) 
   Alcohol cirrhosis, n (%) 47 (12.3) 18 (14.4) 17 (13.2) 12 (9.4) 
   Storage disorders, n (%) 21 (5.5) 4 (3.2) 9 (7.0) 8 (6.3) 
   Other, n (%) 52 (13.6) 20 (16.0) 18 (14.0) 14 (10.9) 
Transplant characteristics 
   Cold ischemia time, hours 8.1 (6.9 - 10.0)  8.3 (6.7 – 10.1) 7.9 (6.7 – 10.2) 8.0 (7.0 – 9.9) 0.77 
   Warm ischemia time, minutes 48.0 (41.0 - 57.0) 48.0 (41.0 – 56.0) 48.0 (41.0 – 58.3) 48.5 (42.0 – 57.3) 0.91 
   Age donor, years 43.7 ± 14.5 43.7 ± 14.3 43.5 ± 15.3 43.8 ± 14.0 0.98 
   Donation after brain death, n (%) 342 (89.5) 106 (84.8) 117 (90.7) 119 (93.0) 0.09 
   Transplantation era, n (%)     0.83 
      1993-1998 118 (30.9) 42 (33.6) 35 (27,1) 41 (32.0)  
      1999-2004 133 (34.8) 43 (34.4) 47 (36.4) 43 (33.6)  
      2005-2010 131 (34.3) 40 (32.0) 47 (36.4) 44 (34.4)  
Transplant complications 
   Acute rejection, n (%) 159 (41.6) 51 (40.8) 53 (41.1) 55 (43.0) 0.93 
   Relaparotomy, n (%) 57 (14.9) 22 (17.6) 21 (16.3) 14 (10.9) 0.24 
   Length of intensive care stay, days 3.0 (1.0 – 7.0) 3.0 (2.0 – 8.5)  3.5 (2.0 – 8.8) 2.0 (1.0 – 5.0) 0.11 
   Pre-transplant MELD score 14.2 (10.0 – 22.2) 14.2 (8.8 – 19.7) 14.8 (10.4 – 24.2)  13.5 (10.3 – 21.4) 0.64 
Medication 
   Calcineurin inhibitor, n (%)     
 
      Cyclosporine 160 (41.9) 48 (38.4) 54 (41.9) 58 (45.3) 0.57 
      Tacrolimus 200 (52.4) 67 (53.6) 68 (52.7) 65 (50.8) 0.87 
   Proliferation inhibitor, n (%)      
      Azathioprine 169 (44.2) 51 (40.8) 56 (43.4) 62 (48.4) 0.50 
      Mycophenolate mofetil 62 (16.2) 20 (16.0) 22 (17.1) 20 (15.6) 0.94 
   Prednisolone, n (%) 328 (85.9) 109 (87.2) 109 (84.5) 110 (85.9) 0.83 
   Prednisolone dose, mg/day   10.0 (7.5 – 10.0) 10.0 (5.0 – 10.0) 10.0 (7.5 – 10.0) 10.0 (7.5 – 10.0) 0.08 
   Cumulative prednisolone dose, g  3.7 (3.0 – 5.5) 3.7 (2.7 – 5.5) 3.7 (2.8 – 4.5) 3.9 (3.6 – 6.6) 0.02 
   Antidiabetics, n (%) 77 (20.2) 30 (24.0) 22 (17.1) 25 (19.5) 0.37 
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   Statins, n (%) 34 (8.9) 10 (8.0) 11 (8.5) 13 (10.2) 0.83 
Data are represented as mean±SD, median (interquartile range) or n (%). Differences were tested by ANOVA or Kruskal Wallis for continuous variables and with χ2- test for 
categorical variables. Cardiovascular disease history was defined as myocardial infarction, cerebrovascular accident and/or peripheral arterial disease.  
BMI, body mass index; BSA, body surface area; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL-cholesterol, 
high-density lipoprotein; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GT, gamma-glutamyltransferase; ALP, alkaline 
phosphatase; NASH: non-alcoholic fatty liver disease. Storage disorders include Wilson’s disease, hemochromatosis and alfa-1-antitrypsin deficiency. Hypertension was 










This article is protected by copyright. All rights reserved. 
Table 2. Creatinine excretion rate according to categories of primary liver disease.  
 
Overall OLT recipients 







Primary liver disease 
    
Acute liver failure 11.8 (10.2-13.9) * 11.9 (9.9 – 14.1) 11.8 (11.3 – 17.6) 
Viral hepatitis 11.3 (8.6-14.3) 8.6 (6.6 – 9.6) 12.6 (11.6 – 13.7) 15.7 (14.9 – 16.9) 
Auto-immune hepatitis 10.8 (8.6-13.4) 8.1 (7.8 – 9.6) 10.2 (8.9 – 12.6) 13.4 (11.5 – 19.1) 
Primary biliary cholangitis 10.5 (8.0-12.5) 7.7 (6.6 – 8.2) 9.2 (8.4 – 12.4) 12.3 (10.9 – 13.5) 
Primary sclerosing cholangitis 13.0 (10.3-15.4) 9.8 (7.9 – 10.7) 12.2 (9.7 – 13.4) 15.4 (14.7 – 18.6) 
Cryptogenic cirrhosis + NASH 11.0 (8.9-13.3) 9.7 (6.7 – 10.9) 11.7 (9.0 – 12.9) 16.0 (14.1 – 18.0) 
Alcohol cirrhosis 10.4 (8.3-13.8) 7.3 (6.3 – 9.2) 12.0 (8.9 – 13.2) 15.4 (13.0 – 17.6) 
Storage disorders 12.9 (10.1-15.7) 9.3 (9.2 – 9.9) 12.9 (11.3 – 14.3) 15.9 (12.6 – 18.0) 
Other 10.4 (8.1-13.1) 7.8 (6.8 – 8.5) 10.2 (9.4 – 12.3) 14.3 (12.7 – 18.4) 
Data are represented as median (interquartile range) CER according to categories of primary liver disease. *, not enough variables for reliable presentation. 
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Table 3. Association of creatinine excretion rate with all-cause mortality (12-months) 
 CER as continuous  
variable (log-base2) 
 Tertiles of CER (mmol/24h) 
    
T1  T2  T3 
 
HR (95% CI) P-value 
 
HR (95% CI) P-value HR (95% CI) P-value Reference 
All-cause mortality,  
no. of events 
104   43  35 
 
26 
Model 1 0.61 (0.41-0.90) 0.01 
 
1.79 (1.10-2.92) 0.02 1.29 (0.78-2.15) 0.32 1.00 
Model 2 0.43 (0.26-0.71) 0.001 
 
2.69 (1.47-4.91) 0.001 1.82 (1.04-3.18) 0.04 1.00 
Model 3 0.47 (0.28-0.81) 0.006 
 
2.58 (1.35-4.93) 0.004 1.77 (1.00-3.14) 0.05 1.00 
Model 4 0.48 (0.25-0.90) 0.02 
 
2.46 (1.21-5.00) 0.01 1.28 (0.65-2.53) 0.47 1.00 
Model 5 0.44 (0.24-0.80) 0.007 
 
2.91 (1.36-6.23) 0.006 2.12 (1.11-4.05) 0.02 1.00 
Model 6 0.45 (0.25-0.79) 0.006 
 
2.92 (1.47-5.82) 0.002 1.93 (1.07-3.49) 0.03 1.00 
Model 7 0.46 (0.26-0.83) 0.009 
 
2.39 (1.21-4.71) 0.01 1.49 (0.81-2.73) 0.20 1.00 
Cox proportional hazards regression analysis was performed to assess the association of creatinine excretion rate with all-cause mortality. 
Model 1: crude  
Model 2: adjustment for age, sex, and body surface area*  
Model 3: model 2 + adjustment for eGFR, proteinuria, primary liver disease, and transplantation era 
Model 4: model 3 + adjustment for cardiovascular disease history, smoking*, SBP, and glucose 
Model 5: model 3 + adjustment for use of calcineurin inhibitors and cumulative prednisolone dose  
Model 6: model 3 + adjustment for liver enzymes (AST, ALT, γ-GT, and ALP) and direct bilirubin 
Model 7: model 3 + adjustment for serum albumin and total cholesterol 
eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; AST, aspartate aminotransferase; ALT, alanine aminotransferase;  
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Table 4. Association of creatinine excretion rate with death-censored graft failure (12-months) 
 CER as continuous  
variable (log-base2) 
          Tertiles of CER (mmol/24h) 
    
T1  T2  T3 
 
HR (95% CI) P-value 
 
HR (95% CI) P-value HR (95% CI) P-value  Reference 
Graft failure,  
no. of events 
44   17  17  10 
Model 1 0.58 (0.32-1.05) 0.07 
 
1.94 (0.89-4.25) 0.10 1.73 (0.79-3.78) 0.17 1.00 
Model 2 0.42 (0.20-0.90) 0.03 
 
2.77 (1.04-7.39) 0.04 2.18 (0.91-5.19) 0.08 1.00 
Model 3 0.40 (0.19-0.84) 0.02 
 
3.20 (1.21-8.44) 0.02 2.55 (1.03-6.32) 0.04 1.00 
Model 4 0.28 (0.11-0.67) 0.004 
 
4.30 (1.37-13.44) 0.01 2.23 (0.74-6.76) 0.16 1.00 
Model 5 0.35 (0.14-0.82) 0.02 
 
3.10 (1.11-8.67) 0.03 2.48 (0.97-6.34) 0.06 1.00 
Cox proportional hazards regression analysis was performed to assess the association of creatinine excretion rate with death-censored graft failure.  
Model 1: crude  
Model 2: adjustment for age, sex, and body surface area* 
Model 3: model 2 + adjustment for eGFR, proteinuria, primary liver disease, and transplantation era 
Model 4: model 3 + adjustment for cardiovascular disease history, smoking*, SBP, and glucose 
Model 5: model 3 + adjustment for use of calcineurin inhibitors and cumulative prednisolone dose  
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No. at risk 125 114 107 79 62
No. of events __0 _12 _19 29 36
No. at risk 129 127 123 98 72
No. of events __0 __3 __7 15 24
No. at risk 128 126 125 98 79






















No. at risk 125 108 _99 68 50
No. of events __0 __8 _10 15 17
No. at risk 129 125 119 92 66
No. of events __0 __2 __5 _8 10
No. at risk 128 123 119 93 73











Figure 1.  Kaplan Meier curves for all-cause mortality (A) and graft failure (B) according to sex-stratified 
tertiles of CER in 382 OLT recipients. 
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Figure 2.  Association of log-transformed (HR per doubling of) CER on all-cause mortality and graft failure in 
382 OLT recipients. Data were fit by a Cox proportional regression model with time-varying covariates based 
on restricted cubic splines with 3 knots. Adjusted for age, sex, and BSA. Reference standard was the median 
CER of the 3rd tertile (i.e. 3.9 mmol/24h log-transformed per doubling of CER equivalent to a CER of 15.1 
mmol/24h). The grey area represents the 95% confidence interval (CI).  
 
 
 
 
